End-stage differentiation of antigen-specific T-cells may precede loss of immune responses against e.g. viral infections after allogeneic stem cell transplantation (SCT). Antigen-specific CD8+ T-cells detected by HLA/peptide multimers largely comprise CD45RA-/CCR7-effector memory (T EM ) and CD45RA+/CCR7-T EMRA subsets. A majority of terminally differentiated T-cells is considered to be part of the heterogeneous T EMRA subset. The senescence marker CD57 has been functionally described in memory T-cells mainly composed of central memory (T CM ) and T EM cells. However, its role specifically in T EMRA cells remained undefined. Here, we investigated the relevance of CD57 to separate human CD8+ T EMRA cells into functionally distinct subsets. CD57-CD8+ T EMRA cells isolated from healthy donors had considerably longer telomeres and showed significantly more BrdU uptake and IFN-γ release upon stimulation compared to the CD57+ counterpart. Cytomegalovirus (CMV) specific T-cells isolated from patients after allogeneic SCT were purified into CD57+ and CD57-T EMRA subsets. CMV specific CD57-T EMRA cells had longer telomeres and a considerably higher CMV peptide sensitivity in BrdU uptake and IFN-γ release assays compared to CD57 + T EMRA cells. In contrast, CD57+ and CD57-T EMRA cells showed comparable peptide specific cytotoxicity. Finally, CD57-CD8+ T EMRA cells partially changed phenotypically into T EM cells and gained CD57 expression, while CD57+ CD8+ T EMRA cells hardly changed phenotypically and showed considerable cell death after in vitro stimulation. To the best of our knowledge, these data show for the first time that CD57 separates CD8+ T EMRA cells into a terminally differentiated CD57+ population and a so far functionally undescribed "young" CD57-T EMRA subset with high proliferative capacity and differentiation plasticity.
Introduction
Monitoring of antigen specific CD8+ memory T cells plays an increasing role after allogeneic stem cell transplantation (SCT) in order to evaluate the efficacy and fate of immune responses against e.g. viral infections [1] or transplantation antigens [2] . Particularly, end-stage a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 differentiation of antigen-specific CD8+ T-cells may precede loss of immune responses. CD8 + memory T cells arise from naïve T cells upon antigen encounter [3] and are functionally very heterogeneous. Human CD8+T cells are commonly classified into four subsets based on the surface expression of the leukocyte common antigen isoform CD45RA and the lymph node addressin CCR7 [4] . Thereby, naïve T N cells (CD45RA+/CCR7+) are separated from central memory T CM (CD45RA-/CCR7+), effector memory T EM (CD45RA-/CCR7-) and T EMRA (CD45RA+/CCR7-) T cells [4, 5] . T CM cells show a high proliferative potential, but a poor effector function. Conversely, T EM cells have an immediate effector function but only limited proliferative potential [6] . In man, the developmental relationship among T CM , T EM and effector cells is still controversial and has been recently reviewed in detail [7, 8] .
Antigen-specific CD8+ T cells detected by HLA/peptide multimer staining largely comprise T EM and T EMRA subsets. However, the relative distribution of T EM and T EMRA may vary considerably depending on the target antigen. For instance, HIV-specific T cells are largely T EM while CMV-specific T cells are mainly of the T EMRA phenotype [9] [10] [11] [12] . To date, the experimental evidence on the functional characterization of T EMRA cells is controversial. Several authors consider T EMRA cells overall as the terminally differentiated effector cells supported by low Interleukin-2 and high interferon gamma secretion [4] , high cytotoxicity [3] , low proliferative capacity and high sensitivity to apoptosis [13] . In contrast, Rufer et al. described heterogeneity within the T EMRA cells and identified CD27+/CD28+/-cells as an intermediate phenotype between naïve and effector cells and CD27-/CD28-cells as late differentiated highly cytotoxic T cells [14] . However, the complexity of subsets with partial functional overlap challenges the longitudinal phenotypical characterization of antigen specific CTLs in the peripheral blood of patients due to their low frequencies and the small available sample sizes. The cell surface molecule CD57, also known as Human Natural Killer 1 (HNK1), might help to reduce the complexity of markers by separating CD8+ T EMRA cells in only two distinct subsets. Brenchley et al. reported that CD57 associates functionally with short telomeres, high sensitivity to apoptosis and replicative senescence in mixed CD8+ memory T cell subsets [15] . Moreover, CD57 expression on CD8+ memory T cells has been shown to strongly correlate with high expression of cytolytic enzymes such as perforin and granzyme A/B [16] . However, due to the differentiation markers used in these studies (i.e. CD45RO or CD45RA combined with CD27 or CD28), the T cell subsets in which CD57 had been functionally described mainly comprised T CM and T EM cells but only partially included CD8+ CD45RA-/CCR7-T EMRA cells. Thus, the role of CD57 specifically in the still ambiguous CD8+ T EMRA population remains undefined. While CD8+ T EMRA cells are mostly considered positive for CD57 [4, 17, 18] , some authors also describe a heterogeneous CD57 expression [3] supporting a distinctive role of CD57 also in CD8+ T EMRA cells.
In this study, we investigated the relevance of CD57 to separate human CD8+ T EMRA cells into two subsets with distinct functional and differentiation capacities.
Materials and methods

PBMC isolation and patient characteristics
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood collected from six healthy donors (3 donors younger and 3 donors older than 45 years) and from 10 patients who underwent allogeneic SCT at the Hannover Medical School (Germany). Patients were treated according to SCT protocols approved by the Institutional Review Board of the Hannover Medical School. Patients and donors gave written informed consent in accordance with the declaration of Helsinki. Analysis was performed with approval of the Institutional Review Board of the Hannover Medical School (2934-2015). 4 males and 6 female patients who received a transplant of bone marrow (1/10) or peripheral stem cells (9/10) at Hannover Medical School between 2012 and 2015 were included in this study. The median age of the patients was 51 years (range 37-66). Underlying diseases were acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Non-Hodgkin's Leukaemia (NHL), Multiple Myeloma (MM), Aplastic anemia (AA) and Myeloproliferative Neoplasm (MPN). 5/10 patients received graft from matched unrelated donors (MUD), 2/10 from mismatched unrelated donor (MMUD) and 3/10 from HLA identical sibling donor. All patients received Cyclosporin (CsA) along with Mycophenolate mofetil (7/10) or methotrexate (3/10) as GvHD prophylaxis. PBMCs were isolated by ficoll gradient, frozen in liquid nitrogen after supplementation in 80% RPMI-1640, 10% fetal calf serum (FCS, Sigma-Aldrich, Missouri, USA) and 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich).
Immunophenotyping and analysis
PBMCs thawed and cultured overnight in IMDM (Lonza, Basel, Switzerland), supplemented with 10% human serum (HS, Sigma-Aldrich) were labelled with anti-CD8-Alexa Fluor700 (Clone: RPA-T8, BD Biosciences, New Jersey, USA), anti-CD3-PE-Cy7 (Clone: UCHT1), anti-CD45RA-PerCP Cy5. 5 
Expansion of CMV specific CD8+ T cells
PBMCs of CMV IgG+ patients after allogeneic SCT were stained with AlexaFluor750 labeled live dead stain (Life Technologies) at 37˚C for 15 min followed by staining with anti-CD3-AlexaFluor700, anti-CD8-PECy7 and PE-labeled CMV 
Sorting of CD8+ T cell subsets
After thawing and culturing overnight in 10% HS / IMDM, PBMCs were labelled with anti-CD8-Alexa Fluor700, anti-CD3-PE-Cy7, anti-CD45RA-PerCP Cy5.5, anti-CCR7-PECF594, anti-CD57-FITC, anti-PD-1-BV421, anti-CD27-BV605, anti-CD28-APC and AlexaFluor750 labeled live/Dead stain. Live/dead and CCR7 staining were performed at 37˚C for 15 mins followed by staining with the rest of the antibodies at 4˚C for 30 mins. Subsequently, cells were sorted on FACS Aria™ II (BD Biosciences). CD57-and CD57+ T EMRA populations of in vitro expanded CMV tetramer+ T cells were separated on FACS Aria™ II (BD Biosciences) after resting in 10% HS/IMDM supplemented with 120 IU/ml of IL-2 for three days and staining with live/Dead stain, anti-CD45RA-PerCP Cy5.5 (Biolegend), CMV Tetramer-PE (MBL International), anti-CD57-FITC and anti-CD4-BV421 at RT for 30 mins. Post-sorting analysis of purified subsets revealed greater than 98% purity. Subsequently, sorted T cell subsets were directly subjected to functional assays.
Cell proliferation assay
The proliferative capacity of T cell subsets of healthy donors and of CMV CTLs was measured by quantification of 5-bromo-2'deoxyuridine (BrdU) incorporation. 
Interferon-γ release
IFN-γ levels in cell culture supernatants collected from BrdU uptake assay was measured by ELISA kit (eBioscience, Vienna, Austria) according to the manufacturer's instructions. The ELISA plate was read at 450 nm (reference 570 nm) in an ELISA reader.
Cytotoxicity assay
PHA blasts (PHAb) positive for the relevant HLA were generated by stimulating PBMCs with 1% Leucoagglutinin PHA-L along with 120IU/IL-2 supplementation every 2-3 days for two weeks in culture. CD4+ PHA blasts (PHAb) were further enriched by MACS and frozen for subsequent use as target cells for CD8 + T cell mediated peptide specific lysis. CD4+ PHAb were thawed and cultured overnight at 37˚C in the presence of 120 IU/ml IL-2, labeled with 3 μM CFSE (Life Technology) in 1 ml 10% HS/IMDM for 10 minutes at 37˚C. The reaction was stopped by 2 ml 10% HS/IMDM, followed by 2 min incubation at 4˚C. After washing twice in PBS, 5 × 10 3 CFSE labeled PHAb in 50 μL 10% HS/IMDM per well were added to a Vbottom 96-well microtiter plate. The relevant peptide concentration in 50 μL 10% HS/IMDM was added and incubated at 37˚C for 60 min. Finally, 1 × 10 4 CMV CTLs were added in a total volume of 150 μL 10% HS/IMDM per well and the plate was centrifuged at 1500 rpm for 5 min without break and incubated further for 4h at 37˚C. Subsequently, cells were stained for anti-CD4-BV421 (Clone: OKT4, Biolegend) as control for the exclusion of intercellular CFSE transfer and anti-CD8-PECy7 (Clone: RPA-T8, BD Biosciences) to identify the effector cells at 4˚C for 30 min. Wells were harvested, 40,000 Flow-Count Fluorospheres and 7AAD (Beckman Coulter) were added just prior to acquisition on BD LSR II. 5000 microbeads were acquired for each sample. Specific lysis of target cells was calculated as: % specific lysis = % dead target cells with effector cells-% dead target cells without effector cells, as previously published [19] .
Absolute telomere length measurement
Absolute telomere length was measured by real time PCR as previously published [20] with slight modifications including a pre-amplification step for application on small cell numbers [21] . 50 cells were sorted in triplicate directly into 4 μl lysis buffer per well of a V-bottom 96 well plate and frozen for subsequent PCR at -20˚C. The pre-amplification was performed on the lysate using the telomere primers (forward: 5 0 (TTAGGG)14 3 0 and reverse:5 0 CAG CAAGTGGGAAGGTGTAATCCGTCTCCACAGACAAGGCCAGGACTCGTTTG 3 0 ) and the single copy reference gene 36B4 primers (forward: 5 0 CAGCAAGTGGGAAGGTGTAATCC-3 0 and reverse: 5 0 CAGCAAGTGGGAAGGTGTAATCCGTCTCCACAGACAAGGCCAGGACTCGTTTG 3 0 ) with the reaction conditions as described [20] . The pre-amplification product was purified using the Zymo PCR clean and concentration kit (Zymo Research, CA, USA). The final elution was made in 44 μl elution buffer. Purified PCR product was used in the subsequent real time PCR using the same primers as above and reaction conditions as described [20] . The methodology was validated for established tumor cell lines of known telomere length and T cell clones by Southern Blot analysis at the Department of Human Genetics, MHH, Hannover (S1 Fig) .
Statistics
All statistical analysis was performed using Prism 5 (GraphPad, California, USA). A p value < 0.05 was considered statistically significant.
Results
Distribution of CD57 in CD8+ T cell subsets
Firstly, the distribution of CD57 in CD8+ T cell subsets in the peripheral blood of six healthy donors was analyzed using 10-color flow cytometry. A representative example of this analysis is shown in Fig 1A. The CD8+ T cells comprised 40% (+/-21) T N cells, 13% (+/-18), T CM cells, 18% (+/-5) T EM and 11% (+/-6) T EMRA cells. All T N and T CM cells were CD57-, whereas T EM and T EMRA cells segregated into 32% (+/-18) and 41% (+/-12) CD57+ cells, respectively (Table 1) . To investigate the CD57 distribution in antigen specific T cells, further studies were applied on CMV specific CD8+ T cells emerging after allogeneic SCT due to the clinical relevance of CMV infections in transplantation and the relative abundance of CMV specific T cells technically facilitating functional experiments. HLA/CMV peptide tetramers were used to identify CMV specific CD8+ T cells in the peripheral blood of 10 patients collected at median 139 days (min. 38/ max. 354) after allogeneic HLA-matched SCT. In accordance with previous reports, there were overall more T EM and T EMRA cells compared to healthy donors [9, 10] . CMV tetramer+ CD8+ T cells comprised only of T EM and T EMRA cells with 43% (+/-21) and 56% (+/-21), respectively (Table 1 ). Further investigation revealed that CD8+ CMV tetramer + T EM and T EMRA cells segregated into 69% (+/-21) and 58% (+/-25) CD57+ cells, respectively (Table 1) . A representative example of this analysis is shown in Fig 1B. 
Functional characterization of CD57+/-CD8+ T EM and T EMRA subsets
In order to investigate the functional differences between CD8+ T N , T CM , CD57+/-T EM and CD57+/-T EMRA subsets, CD8+ T cells were enriched from the peripheral blood of healthy donors and subsequently FACS sorted into T N , T CM , CD57+ and CD57-T EM and T EMRA cells. The sorted cells were analyzed for telomere length and-subsequent to PHA and IL-2 stimulation-for BrdU uptake and IFN-γ release. Longest and comparable telomeres were found for T N , CD57-T EM and CD57-T EMRA cells (Fig 2A) . CD57+ T EM cells had shorter telomeres than CD57-T EM cells by trend. Additionally, telomere length was significantly shorter in CD57+ compared to CD57-T EMRA cells (p = 0.016, Mann-Whitney U test, Fig 2A) . There were no significant differences in BrdU uptake between T N and T CM , CD57-T EM and CD57-T EMRA cells (Fig 2B) . Conversely, CD57+ cells showed a significantly lower BrdU uptake compared to CD57-cells both in T EM and T EMRA subsets (p = 0.004 and p = 0.026, respectively; Mann-Whitney U test; Fig 2B) . IFN-γ release was found to be highest for T CM and low for T N , CD57+ T EM and T EMRA cells. CD57+ cells released less IFN-γ compared to CD57-cells both in T EM and T EMRA subsets. However, this difference between CD57-and CD57+ cells was significant only for T EMRA cells (p = 0.032; Mann-Whitney U test; Fig 2C) .
Functional characterization of CMV specific CD57+/-CD8+ T EMRA subsets
In order to get further insights into the relevance of CD57 in CD8+ antigen specific T EMRA cells, the functional properties of CD8+ CMV specific T EMRA subsets with and without CD57 expression were compared. CMV tetramer+ CD8+T cells were isolated from the peripheral blood of 3 patients after allogeneic SCT by FACS sorting and expanded on autologous feeder cells in vitro to cell numbers sufficient for functional studies. Phenotypic analysis of CMV tetramer+ CD8+T cells for CD45RA/CCR7 in vivo and after sorting and expansion in vitro revealed a comparable distribution of T EM and T EMRA subsets with a trend towards more CD57-cells within the T EMRA subset (Fig 3A) . Subsequently, these in vitro expanded CMV specific CTLs were further purified into CD57+ and CD57-T EMRA subsets by FACS (Fig 3B) . The CD57+ and CD57-T EMRA cells were directly analyzed for telomere length (Fig 3C) and for CMV peptide dependent BrdU uptake (Fig 3D) , IFN-γ release (Fig 3E) and cytotoxicity (Fig 3F) . CD57+ T EMRA cells showed significantly shorter telomeres compared to CD57-T EMRA cells in 2/3 patients derived CMV CD8+ T cells (Fig 3C) . BrdU uptake and IFN-γ release upon stimulation with target cells loaded with increasing CMV peptide concentrations revealed considerably higher BrdU uptake (Fig 3D) and IFN-γ release (Fig 3E) for CD57-T EMRA cells than for CD57+ T EMRA cells. In contrast, CD57+ T EMRA cells showed only slightly higher cytotoxicity against targets loaded with increasing concentrations of CMV peptide than CD57-T EMRA cells (Fig 3F) .
Differentiation potential of CD8+ CD57-and CD57+ T EMRA cells
Finally, the fate of CD8+ CD57+ and CD57-T EMRA cells after PHA +IL-2 stimulation was studied in in vitro. CD8+ CD57+ and CD57-T EMRA cells were highly purified from peripheral blood of 5 healthy donors by FACS sorting (Fig 4A) . The purity was confirmed by FACS analysis to be >98% after sorting. Subsequently, sorted T cell subsets were stimulated with PHA supplemented with 120 IU/ml IL-2 every two days and kept in culture for 7 days. Subsequently, T cells were phenotypically characterized based on cell surface expression of CD45RA, CCR7 and CD57 (Fig 4B) . Overall CD57-T EMRA cells by trend were less susceptible to cell death upon PHA + IL-2 stimulation than CD57+ T EMRA cells (p = 0.0625, Wilcoxon matched-pairs signed rank test, Fig 4C) . There was a significant loss of CD45RA surface expression on CD57-T EMRA cells compared to CD57+ T EMRA cells (p = 0.0355, Wilcoxon matched-pairs signed rank test, Fig 4D) . Moreover, 12(+/-8) % of CD57-T EMRA cells acquired CD57 expression (exemplified in Fig 4B) . These findings, suggest that CD57-T EMRA cells show differentiation potential towards T EM , which is largely absent on CD57+ T EMRA cells.
Discussion
In this study, we have shown for the first time experimentally the relevance of CD57 as a marker to separate human antigen specific CD8+ T EMRA cells into functionally distinct subsets. Thereby, we functionally characterized a previously undescribed "young" CD57-T EMRA population that differs by its high proliferative and differentiation plasticity from its CD57 + terminally differentiated counterpart. So far, phenotypic characterization of human antigen specific CD8+ T cells is commonly based on the CD45RA/CCR7 marker system. Among the memory subsets, the CD8+ CD45RA+CCR7-T EMRA cells had been either interpreted as terminally differentiated T cells in total [4] or they were often excluded from interpretation in monitoring studies of antigen specific immune responses due to the complexity of subdivision using current phenotypic markers [22, 23] . Despite CD57 is mostly considered as general T cell senescence marker [15] its role specifically in CD8+ T EMRA cells was so far undefined. Our data show that around 11% of CD8+ T cells in the peripheral blood of healthy donors are T EMRA cells, of which 41% are CD57+. These data are comparable to previous data of Hamann et al. describing around 50% of T EMRA cells being CD57+ and support the previously described phenotypical heterogeneity of CD8+ T EMRA cells [3, 14] . Moreover, 56% of CD8+ CMV specific CTLs after allogeneic SCT are T EMRA cells, of which 58% are CD57+. These data are comparable to previous findings showing that CMV-specific T cells are mainly of the T EMRA phenotype [9] [10] [11] [12] . Healthy donor derived CD8+ CD57-T EMRA cells showed a telomere length that was by trend even longer than that of T N cells, while telomere lengths of CD57+ T EMRA cells were the shortest measured in our tested T cell subsets. Also previous reports showed that CD8+ T EMRA cells can be subdivided into populations with long [14] and short [24] telomeres, however based on the differentiation marker system CD27 and CD28. The long telomeres in CD57-T EMRA cells associated well with high T cell proliferation and INF-γ release in our study, while short telomeres in CD57+ T EMRA cells associated with a low proliferative response and INF-γ release in response to PHA stimulation. Similarly, highly purified CMV specific CD57-T EMRA cells showed a considerably higher sensitivity in response to CMV peptides with regard to T cell proliferation and INF-γ release but slightly lower peptide sensitivity in cytotoxicity assays compared to CMV specific CD57+ T EMRA cells. These data demonstrate that CD57 separates CD8+ T EMRA cells based on a considerably different proliferative capacity. We assumed that this higher proliferative capacity of CD8+ CD57-T EMRA cells might also associate with a higher differentiation capacity compared to the CD57+ counterpart. Our data showed that in vitro stimulation of highly purified CD8+ CD57-T EMRA cells resulted in a partial loss of CD45RA suggesting the emergence of T EM cells. Additionally, some CD8+ CD57-T EMRA also gained CD57 expression. In contrast, CD8+ CD57+ T EMRA cells hardly changed phenotypically and were more susceptible to cell death than CD8+ CD57-T EMRA cells after stimulation. excision circles (TRECs) which indicate maturation of T cells, that the CD8+ CD27+ T EMRA subset comprises cells that are evolving from a naïve differentiation stage [14] . Potentially, the position of CD57-T EMRA cells within the differentiation pathway of human T cells needs to be refined based on studies on whether CD57-T EMRA cells might even directly arise from T N cells. The capacity of CD57 to separate CD8+ T EMRA cells into subsets with contrasting functional and developmental properties may have a considerable impact on the monitoring of antigen specific CTLs in patients after HSCT. Evidently, longitudinal studies on immune responses are often limited by the low frequency of antigen specific T cells in the peripheral blood and by the available patient sample size [25] . Therefore, phenotypic markers of polychromatic panels for the characterization of antigen specific CTLs need to be limited to a minimum in order to end up with subpopulation sizes large enough to allow statistical comparisons. Consequently, the selected markers should not provide an informative overlap [18] . Phenotypic analysis of the CD8+ T EMRA population in healthy donors revealed that only 63 (+/-9) % of CD27-/CD28-T EMRA cells are positive for CD57 (S1 Table) . Conversely, 95 (+/-2)% of CD57+ T EMRA cells are CD27-/CD28-(S2 Table) which were shown to have end stage differentiation properties [14] . These data suggest that CD27-/CD28-T EMRA cells are not a homogenous population based on CD57 expression and that CD57+ T EMRA cells are a subset of CD27-/CD28-T EMRA cells. Since 37 (+/-9)% of CD27-/CD28-cells are also CD57-(S1 Table) and absence of CD57 indicated high proliferative potential in our and other studies [16] , CD27-/CD28-cells are not entirely terminally differentiated. Thus, in contrast to absence of both CD27 and CD28, CD57 might be an excellent marker to uniquely distinguish terminally differentiated CD8+ T EMRA from others. Thereby, CD57 may help to restrict the number of functionally relevant markers necessary to characterize T EMRA cells in studies monitoring antigen specific T cell responses. The clinical importance of CD57 as a singular marker had been previously shown by Scheinberg et al. who found that negativity for CD57 predicts longterm persistence of donor derived CD45RO+ CD27-CMV specific T cells in the recipient and confers protection against viral reactivation after HSCT [26] . Additional studies are required to assess whether also the absence of CD57 expression on CMV specific T EMRA cells (which are CD45RO-) associates with the persistence of CMV immune responses after allogeneic SCT.
In conclusion, CD57 alone might reduce the complexity of currently used phenotypic markers in polychromatic panels to identify end-stage differentiated CD8+ T EMRA cells. Transcriptional profiling of the CD57+/-T EMRA cells may further help in confirming the functional role of CD57 and in defining the differentiation status of T EMRA cells. Finally, we have shown that CD57 separates CD8+ T EMRA cells into a terminally differentiated CD57+ population and a so far functionally undescribed "young" CD57-T EMRA subset with high proliferative capacity and differentiation plasticity.
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Fig. Validation of absolute telomere length quantification. Absolute telomere length was quantified by qPCR on DNA isolated from 50 cells including a pre-amplification step and validated by southern blot hybridization using 1μg genomic DNA isolated from 2x106 cells. The range of measurement was defined by absolute telomere length analysis for the human T cell leukaemia cell line 1301 as reference for long telomeres and the breast cancer cell line cal51 as reference for short telomeres. Additionally, a CMV CTL clone of unknown telomere length was measured. (TIF) S1 
